erasca Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More By xconomy.com Published On :: Fri, 01 May 2020 12:55:07 +0000 Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after preliminary data released this week from a federally funded trial involving more than 1,000 […] Full Article Boston blog main Boston top stories Boulder/Denver blog main Boulder/Denver top stories Detroit blog main Detroit top stories Europe blog main Europe top stories Indiana blog main Indiana top stories National National blog main National top stories New York blog main New York top stories Raleigh-Durham blog main Raleigh-Durham top stories San Diego blog main San Diego top stories San Francisco blog main San Francisco top stories Seattle blog main Seattle top stories Texas blog main Texas top stories Wisconsin blog main Wisconsin top stories ADC Therapeutics Adicet Bio Affinia Therapeutics Akili Interactive Alphabet Alzheimer's disease AMAG Anthony Fauci Aurinia Avadel Pharmaceuticals Avalyn Pharma Axsome Therapeutics BioNtech Biotech cancer clinical trials coronavirus COVID-19 Dascena David Cook Depression Digital Health Drug Development Erasca FDA Financing Forma Gene Therapy Genespire Gilead Sciences google Idiopathic Pulmonary Fibrosis Imvax IPO Joe Miller Kelly Martin Life Sciences Lymphoma Lyra Therapeutics Machine Learning Mark Exley Martin Huber Mirum ModeRNA National Institute of Allergy and Infectious Diseases Neurocrine Biosciences neurodegeneration Parkinson's Disease Pear Therapeutics Pfizer Radius Regeneron Pharmaceuticals remdesivir resTORbio Roche Rome Therapeutics San Raffaele-Telethon Institute for Gene Therapy Sanofi Scott Myers SuperNus Pharmaceuticals US WorldMeds Vaccine Valneva Venture Capital Vertex Pharmaceuticals Xilio
